Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL7337591

COc1cc2ccc(C(=N)N)cc2cc1OC.O=C(O)C(F)(F)F

nearest known ligand 0.51

Full drug profile on Sugi Atlas →

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PLG P00747 4/20 0.51
F2 P00734 4/20 0.51
F12 P00748 3/20 0.51
F10 P00742 1/20 0.51
F11 P03951 1/20 0.51
PLAU P00749 9/20 0.50
PRSS1 P07477 6/20 0.47
KLKB1 P03952 2/20 0.45
KLK1 P06870 2/20 0.45
PLAT P00750 1/20 0.45
CA12 O43570 1/20 0.44
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
CA4 P22748 1/20 0.44
CA6 P23280 1/20 0.44
CA7 P43166 1/20 0.44
TPMT P51580 1/20 0.44
CA9 Q16790 1/20 0.44
CA14 Q9ULX7 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL7337885 0.83 PLAU (0.55) PLGF2F12F10F11
Trifluoroacetic Acid SCHEMBL7337301 0.83 PLAU (0.64) PLGF2PLAUPRSS1KLK1
Trifluoroacetic Acid SCHEMBL7335260 0.82 PLAU (0.53) PLGF2PLAUPRSS1KLK1
Trifluoroacetic Acid SCHEMBL7333611 0.80 PLAU (0.56) PLGF2F10PLAUPRSS1
Trifluoroacetic Acid SCHEMBL7337450 0.80 PLAU (0.55) PLGF2F12F10PLAU
Trifluoroacetic Acid SCHEMBL7336904 0.79 PLAU (0.59) PLGF2PLAUPRSS1KLK1
Trifluoroacetic Acid SCHEMBL7339921 0.77 PLAU (0.57) PLGF2F10PLAUPRSS1
Trifluoroacetic Acid SCHEMBL7345791 0.77 PLAU (0.84) PLGF2PLAUPRSS1KLK1
Trifluoroacetic Acid SCHEMBL7333225 0.77 PLAU (0.73) PLGF2PLAUPRSS1KLK1
SCHEMBL7567274 0.77 LCK (0.61) PLGPLAUPLATCA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010049374-A1 Urokinase inhibitors STEELE ANDREW W (US) 2001-12-06 US claimed
EP-1000018-A2 UROKINASE INHIBITORS Abbott Laboratories (US) 2000-05-17 EP claimed
WO-1999005096-A2 UROKINASE INHIBITORS ABBOTT LABORATORIES (US) 1999-02-04 WO claimed
US-20010049374-A1 Urokinase inhibitors STEELE ANDREW W (US) 2001-12-06 US disclosed
US-6284796-B1 NAPHTHAMIDINE COMPOUNDS ABBOTT LABORATORIES 2001-09-04 US disclosed
US-6258822-B1 ENZYME INHIBITORS OF NAPHTHALENE AMIDINE COMPOUNDS ABBOTT LABORATORIES 2001-07-10 US disclosed
EP-1000018-A2 UROKINASE INHIBITORS Abbott Laboratories (US) 2000-05-17 EP disclosed
WO-1999005096-A2 UROKINASE INHIBITORS ABBOTT LABORATORIES (US) 1999-02-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010049374-A1 Urokinase inhibitors SERPINE1, PLAU, SERPINB1 PLG 10/4885F2 38/4885F12 33/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.